Dr. Amy Ryan, Associate Professor of Anatomy and Cell Biology and Associate Director of the Center for Gene Therapy at the University of Iowa, highlights potential mechanisms underlying immune complications observed in CF patients despite modulator treatment. She discusses an integrated approach combining physics-based models, gene-edited immune cells, and lung-on-chip technologies, which holds promise for advancing personalized cellular therapies for CF. This presentation was part of CFRI's 37th National CF Education Conference.
CFRI's 37th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Viatris, Gilead Sciences, AbbVie, and the Boomer Esiason Foundation.

Ver todos los episodios